News

Article

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

Red blood cell | - stock.adobe.com

Red blood cell | - stock.adobe.com

Prophylactic treatment with RGI-2001, a natural killer (NK) T-cell activator, in combination with tacrolimus and methotrexate led to a significant reduction in the incidence of grade II to IV acute graft-vs-host disease (aGVHD) compared with the CIBMTR control in patients with hematologic malignancies who underwent allogeneic hematopoietic cell transplant (allo-HSCT), according to findings from the phase 2b RGI-2001-301 trial (NCT04014790) presented during the 2024 AACR Annual Meeting.1

The 1-year overall survival (OS) rate was 91.7% with RGI-2001 (n = 40) vs 79.2% with CIBMTR (n = 160; OR, 3.08; 95% CI, 1.03-9.17; P =.04). The 1-year relapse-free survival rates were 12.5% (n = 38) vs 15.9%, respectively (n = 142; OR, 1.31; 95% CI, 0.51-3.34; P =.57). The rates of grade II to IV aGVHD-free survival at day 180 were 72.9% (n = 36) and 50.7% (n = 103; OR, 2.78; 95% CI, 1.37-5.66; P =.005). The rates of grade III to IV aGVHD-free survival at day 180 were 91.7% (n = 44) and 77.3% (n = 157; OR, 3.36; 95% CI, 1.13-9.94; P =.03).

“Patients treated with RGI-2001 and tacrolimus/methotrexate had significantly lower rates of grade II to IV aGVHD 100 and 180 days post-alloHSCT compared with CIBMTR control. OS is significantly increased while relapse is not changed for patients receiving RGI-2001,” Calvin K. Lee, MS, scientist at Pfizer, and coauthors wrote in the poster.

aGVHD is associated with significant morbidity and mortality, resulting from donor-derived T-cell attacks on an immunosuppressed environment. NK T cells and T-regulatory cells (Tregs) are critical in the prevention of aGVHD.

RGI-2001 is a liposomal formulation of the CD1d ligand a-GalCer that can activate NK T cells and Tregs. In a previous phase 2a trial, a single dose of RGI-2001 100 µg/kg led to increased Treg counts, which was associated with a lower incidence of aGVHD.

Additionally, RGI-2001 was previously evaluated with tacrolimus/methotrexate as prophylaxis for aGVHD in the phase 2b RGI-2001-003 study (NCT04014790) in patients undergoing allo-HSCT. Patient blood samples were evaluated for expansion of NK T cells, Tregs, and other immune cell subsets. The results revealed a lower incidence of aGVHD in patients who received RGI-2001 vs the control. Moreover, higher levels of NK T cells and Tregs were found in patients who received RGI-2001 and did not develop aGVHD.2

In this phase 2b study, investigators further evaluated the prophylactic potential of the agent through repeat dosing.1

Regarding baseline characteristics in the RGI-2001 arm, the median age was 52 years (range, 21-65). Most patients were White (92%), male (56%), and had acute myeloid leukemia (AML; 54%), acute lymphoblastic leukemia (ALL; 23%), or myelodysplastic syndrome (MDS; 15%). The most common donor type and graft source was 8/8 unrelated (67%) and PBSC (81%), respectively. The majority of patients received fludarabine and busulfan conditioning (83%) and all had received calcineurin inhibitors (CNIs) plus methotrexate for GVHD prophylaxis.

In the CIBMTR cohort, the median age was 50 years (range, 18-66). Most patients were White (86%), male (54%), and had AML (52%), ALL (27%), or MDS (14%). The most common donor type and graft source was 8/8 unrelated (61%) and PBSC (83%), respectively. The majority of patients received fludarabine and busulfan conditioning (69%) and 99.5% had received CNI plus methotrexate for GVHD prophylaxis.

The incidence of aGVHD was also consistently lower with RGI-2001 (n = 48) compared with CIBMTR (n = 207) at different time points. The rates of II to IV aGVHD at day 100 were 22.9% with RGI-2001 vs 38.8% with CIBMTR (OR, 2.29; 95% CI, 1.08-4.85; P =.030). At day 180 these rates were 22.9% vs 42.8%, respectively (OR, 2.68; 95% CI, 1.27-5.65; P =.010). The rates of grade III to IV aGVHD at day 100 were 4.2% vs 12.4%, respectively (OR, 3.25; 95% CI, 0.74-14.36; P =.119). At day 180 these rates were 4.2% vs 13.9%, respectively (OR, 3.65; 95% CI, 0.83-16.04; P =.086). However, the 1-year rate of moderate to severe chronic GVHD was 33.3% in both arms (OR, 1.02; 95% CI, 0.52-1.98; P =.961).

Additional results demonstrated evidence of peripheral NK T-cell expansion at day 28 in patients who derived clinical benefit from RGI-2001. Notably, the mean levels of absolute Tregs at day 42, 1 week after the last dose of RGI-2001, were higher in patients who were alive and had not developed grade II to IV aGVHD by day 180 vs those who had died and/or developed aGVHD.

The authors also noted that a substantial proportion of activated Tregs were proliferating, and to a higher degree compared with nonactivated Tregs. The proliferation occurred to a greater extent after treatment compared with baseline samples, which was consistent with results from the phase 1/2a RGI-2001-002 trial (NCT01379209).

“[This study] provides further evidence regarding RGI-2001’s impact on aGVHD, Treg activation and NK T-cell populations,” study authors concluded.

References

  1. Lee CK, Caron C, Strukel S, et al. Phase 2b study of alloHSCT patients receiving RGI-2001, an NKT cell activator, demonstrates protection from acute GVHD, correlating with increased NKT and Treg cell number in patient blood. Presented at the 2024 AACR Annual Meeting; April 5-10, 2024; San Diego, CA. Abstract CT242.
  2. Chen YB, Saad A, Farhan SY, et al. RGI-2001 infusion for prevention of acute Gvhd after allogeneic hematopoietic cell transplantation. Blood. 2022;140(suppl 1):1877-1878. doi:10.1182/blood-2022-162512
Related Videos
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Minoo Battiwalla, MD, MS